A Randomized Controlled Trial of the Efficacy and Safety of CCX282-B, an Orally-Administered Blocker of Chemokine Receptor CCR9, for Patients with Crohn’s DiseaseSatish Keshav, Ole Haagen Nielsen, S Howaldt et al.|PLoS ONE|2013Cited by 134